

AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

LISTING OF CLAIMS:

1. (currently amended) A method for managing batches of immunocompetent cells collected from human or animal subjects for deferred use, comprising for each of said human or animal subjects the following steps:

- conditioning and preserving successively collected batches of immunocompetent cells, into one or more storage centers, and

- constituting and enhancing from collected batches a personal library of immunocompetent cells, said personal library cumulating contains a sum of immunity information stored in the walls of the collected immunocompetent cells from one or more batches of immunocompetent cells,

- during successive collections or batches, collecting information characteristic of the status of health and/or the psychological status of said human or animal subject, said status-characterizing information being obtained by processing measurements made on samples selected from the group consisting of blood, fluid, secretions, hair and combinations thereof from said human or animal subject, said status-characterizing

information collecting being effected obtained before or during the immunocompetent cells collection,

- processing said status-characterizing information for determining the subject's identity data,

- ~~storing, all along said steps~~ continuous storing through each of the steps, the subject's identify identity data into a cell management database,

- ~~upon a request for re-use from a cell treatment entity~~, performing an identification of the personal batches of cells by consulting said cell management database, and receiving from said cell management database said subject's identity data obtained by successive status-characterizing information processing, upon receiving a request concerning said batches of immunocompetent cells from a cell treatment entity,

- determining parameters of a deferred-use protocol of said batches of immunocompetent cells, by processing said successively collected subject's identity data, and

- providing said cell treatment entity with said identified personal batches of cells and with said deferred-use protocol parameters.

2. (currently amended) The method according to claim 1, wherein the status-characterizing information comprise bioelectronic information resulting from processing respective measures of pH, oxidation-reduction potential Rh2 and resistivity

p of blood previously collected on said human or animal subject  
~~(Vineent's bioelectronic method)~~.

3. (withdrawn) The method according to claim 1, wherein status-characterizing information comprise information obtained by processing sensible crystallization images of blood previously collected on said human or animal subject.

4. (previously presented) The method according to claim 1, wherein the status-characterizing information and the immunity information stored in the immunocompetent cells of said human or animal subjects are entered into an expert system used for determining parameters for deferred-use protocols.

5. (currently amended) The method according to claim 4, wherein said expert system ~~is arranged for providing~~ provides an interpretation of said status-characterizing information and said immunity information with respect to a particular gene.

6. (withdrawn) The method according to claim 1, further comprising implementing said method in a therapeutic protocol including re-injecting lymphocytes on a human or animal subject, wherein the previously collected and preserved immunocompetent cells are submitted to an ex-vivo process before being re-injected.

7. (withdrawn) The method according to claim 6, further comprising implementing said method in a therapeutic protocol including re-injecting lymphocytes T with a specific cytotoxic activity after ex-vivo expansion.

8. (previously presented) The method according to claim 6, further comprising implementing said method in a therapy protocol including a step for checking the harmlessness of the lymphocytes before re-injection.

9. (previously presented) The method according to claim 8, further comprising implementing said method in a therapy protocol including a checking step comprising a test of the oxidative stress of the lymphocytes before re-injection, wherein said lymphocytes are aggressed by free radicals.

10. (previously presented) The method according to claim 9, further comprising implementing said method in a therapy protocol including an oxidative stress test for checking various therapy ways for an ex vivo processing and suitability of said therapy ways with the concerned human or animal subject.

11. (withdrawn) The method according to claim 6, further comprising implementing said method in a therapy protocol including an ex vivo processing between lymphocytes and a vaccine before re-injection.

12. (withdrawn) The method according to claim 6, further comprising implementing said method in a therapy protocol including an ex vivo processing and an allergic desensitization of the lymphocytes before re-injection.

13. (withdrawn) The method according to claim 6, further comprising implementing said method in a therapy protocol

including a step for re-injecting lymphocytes by the lymphatic way.

14. (withdrawn) The method according to claim 6, further comprising implementing said method in a therapy protocol for transfusing blood from a donor to a receiver, said protocol including substituting lymphocytes from said donor by lymphocytes from said receiver.

15. (previously presented) The method according to claim 1, further comprising implementing said method in a gene therapy protocol.

16. (currently amended) The method according to claim 1, further comprising ~~before the step for~~ cryo-preserving a batch of immunocompetent cells, ~~a step of cryogenizing said batch in view of annihilating antibodies present within said batch.~~

17. (previously presented) The method according to claim 20, further comprising before any re-use of a batch of immunocompetent cells previously collected, a step for checking the annihilation of the antibodies within said batch.

18. (previously presented) The method according to claim 1, further comprising during conditioning a batch of immunocompetent cells previously collected, a step for immunomagnetically selecting purified lymphocytes or monocytes.

19. (currently amended) A system for managing batches of immunocompetent cells collected from human or animal subjects

for their deferred use, said system comprising for each of said human or animal subjects:

- means for conditioning and preserving batches of immunocompetent cells successively collected, into one or more storage centers,

- means for constituting and enhancing from said collected batches a personal library of immunocompetent cells, said personal library cumulating a sum of immunity information stored in the walls of collected immunocompetent cells from one or more batches of immunocompetent cells,

- means for collecting, during successive collections of batches, information that is characteristic of said human or animal subject's status of health and/or psychological status, before or during immunocompetent cells collection, said status characterizing information being obtained by processing measurements made on samples selected from the group consisting of blood, fluid, secretions, hair and combinations thereof from said human or animal subject,

- means for processing said status-characterizing information in view of determining to determine said subject's identity data,

- means for storing said subject's identity data successively determined into a cell management database,

- means for performing, upon a request for re use from a cell treatment entity, an identification of the personal

batches of cells ~~to including~~ and a means for consulting said cell management database,

- means for determining parameters of a deferred-use protocol for said batches of immunocompetent cells from said human or animal subject's personal library, by processing said successively collected subject's identity data, and

- means for providing said cell treatment entity with said identified personal batches of cells and with said determined deferred-use protocol parameters.

20. (previously presented) The system according to claim 19, further comprising means for getting status-characterizing by processing a blood sample collected on said human or animal subject.

21. (previously presented) The system according to claim 20, further comprising means for getting bio-electronic information by processing respective measures of the pH, the oxidation-reduction potential and the resistivity of blood previously collected on said human or animal subject.

22. (currently amended) The system according to claim 19, further comprising means for getting information from a capillary study ~~on elements~~ of said human or animal subject's hair system.

23. (currently amended) The system according to claim 19, further comprising means for controlling ~~and enhancing~~ an expert system from information characteristic of the status of

human or animal subject's and from immunity information stored in said human or animal subject's immunocompetent cells, ~~in view of determining to determine~~ parameters for deferred-use protocols.

24. (previously presented) The system according to claim 23, further comprising means for providing an interpretation of said human or animal subject's status-characterizing information and said immunity information, with respect of a particular gene.

25. (previously presented) The method according to claim 1, further comprising:

- processing said characteristic information in an information system for determining parameters of said deferred-use protocol, and

- storing said processed information in a cell management data base.

26. (canceled without prejudice)

27. (withdrawn) A method for managing batches of immunocompetent cells collected from a subject for deferred use, the method comprising:

conditioning and preserving successively collected batches of immunocompetent cells in one or more storage centers; and

obtaining from the collected batches a personal library of immunocompetent cells, said personal library characterized using cell surface markers.

28. (withdrawn) The method of claim 27, further comprising:

gathering information characteristic of health status and/or the psychological status of said subject, said status-characterizing information being obtained by analyzing samples of blood and/or fluid and secretions and/or hair collected from the subject;

processing said status-characterizing information for determining the subject's identity data; and

storing the subject's identity data into a cell management database.

29. (withdrawn) The method of claim 28, further comprising:

obtaining a request for the preserved cells of a subject;

identifying the batches for the subject using the cell management database;

determining parameters of a deferred-use protocol for said batches of immunocompetent cells; and

providing said identified personal batches and said deferred-use protocol parameters.

30. (previously presented) A method for managing batches of immunocompetent cells, the method comprising:

collecting successive batches of immunocompetent cells;

gathering information characteristic of health status and/or the psychological status of said subject, said status-characterizing information being obtained by analyzing samples of blood and/or fluid and secretions and/or hair collected from the subject before or during the immunocompetent cells collection;

determining the subject's identity data using said status-characterizing information; and

storing the subject's identity data in a cell management database.

31. (previously presented) A method for managing batches of preserved immunocompetent cells from a subject stored at one or more storage centers, the method comprising:

obtaining a request for the preserved cells of a subject;

identifying the batches for the subject using a cell management database;

determining parameters of a deferred-use protocol for said batches of immunocompetent cells; and

providing said identified personal batches and said deferred-use protocol parameters.